LL37 PTMs can impair its antimicrobial capacity (11), while autoantibodies against LL37 have been implicated in the pathogenesis of autoimmune diseases such as systemic lupus erythematosus (SLE) (12, 14–16). Here, CAMP is linked to systemic lupus erythematosus.